REMEDIUMREMEDIUM1561-59362658-3534Joint-Stock Company Chicot162210.32687/1561-5936-2023-27-2-105-112Original ArticleFeatures of modeling the course and outcomes of diseases in the clinical and economic analysis of drugs in oncology — a review of the models usedTolkushinAlexander G.001KhabrievRamil U.002Eurasian Academy of Good Practices, Moscow, RussiaN. A. Semashko National Research Institute of Public Health, Moscow, Russia15122023210511210102025Copyright © 2023,2023Purpose: to determine current trends in modeling the course and outcomes of diseases in the course of clinical and economic studies of drugs in oncology. A review was made of 108 publications presenting the results of clinical and economic (cost-effectiveness) studies of drugs in oncology using simulations published in the first half of 2022 and the second half of 2021. Of the studies reviewed, 98% were performed using a Markov model or a split survival model. Most models include 3 states: no progression (stable state), progression, and death. As a result, 98% of studies calculated the number of quality life years (QALYs) as a measure of effectiveness. Strict preference (reducing costs and increasing efficiency) was found in only 9% of studies. 56% of publications are made in the USA and China. As sources of initial data for modeling, 99% of authors use the results of clinical trials. The current trends in modeling in the framework of clinical and economic studies of drugs in oncology include the consistency of modeling designs and categories of results that allow their comparison, the prevalence of works by authors from China and the United States.clinical and economic analysispharmacoeconomic studiesmalignant neoplasmsoncologycancermodelingdrugsклинико-экономический анализфармакоэкономические исследованиязлокачественные новообразованияонкологияракмоделированиелекарственные препараты[Yagudina R. I., Skulkova R. S. Fundamentals of pharmacoeconomical analysis. Scientific Centre for Expert Evaluation of Medicinal Products bulletin. 2011;2:56—59. (In Russ.)][Zvonarev S. V. Fundamentals of mathematical modeling: textbook. Yekaterinburg; 2019. (In Russ.)][Kulikov A. Yu., Nguyen T. T., Tikhomirova A. V. Methodology of modeling in pharmacoeconomics. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2011;4(4):8—17. (In Russ.)][Ichimura T., Nomura H., Shimizu H. et al. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer. Pharmazie. 2021;76(9):450—454. doi: 10.1691/ph.2021.1031][Grau S., Solano C., García-Vidal C. et al. Cost analysis of the use of voriconazole, posaconazole and micafungin in the primary prophylaxis of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants. J. Health Econ. Outcomes Res. 2015:3(2):153—161. doi: 10.36469/9832][Tolkushin A. G., Moiseeva T. N. Comparison of the original drug filgrastim (Neupogen) with a Russian reproduced drug (Leukostim) for the prevention and treatment of neutropenia against the background of cytostatic polychemotherapy of patients with advanced stages of lymphogranulomatosis: cost-effectiveness analysis and cost minimization. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2008;(2);22—27. (In Russ.)][Kolbin A. S., Kurylev A. A., Proskurin M. A., Balykina Yu. E. The use of everolimus and sorafenib in metastatic kidney cancer: Cost-effectiveness analysis and budget impact analysis. Medical Technologies. Assessment and choice. 2012;(2):72—78. (In Russ.)][Omelyanovsky V. V., Avksentieva M. V., Krysanov I. S. et al. Clinical and economic analysis of the use of dasatinib and nilotinib in the second-line therapy of chronic myeloid leukemia in patients resistant to imatinib. Medical Technologies. Assessment and choice. 2011;(2):30—36. (In Russ.)][Kosolapov E. G., Kochenkov F. S., Zyryanov S. K., Gladkov O. A. Clinical and economic analysis of the use of pembrolizumab in unresectable and metastatic melanoma compared with targeted therapy. Good clinical practice. 2017;(2):12—24. doi: 10.24411/2588-0519-2017-00011 (In Russ.)][Avksentiev N. A., Derkach E. V., Makarov A. S. Pharmacoeconomical study of the use of enzalutamide, abiraterone and kabazitaxel after chemotherapy in patients with metastatic castration-resistant prostate cancer. Medical Technologies. Assessment and choice. 2018;(3):62—74. (In Russ.)][Yagudina R. I., Babiy V. V. Survival modeling in pharmacoeconomical research: Markov model and model of divided survival. Pharmacoeconomics. Theory and practice. 2017;5(2):13—17. (In Russ.)][Krysanov I. S., Bunyatyan N. D. Basic principles of modeling the «transition of states» in clinical and economic analysis. Bulletin of the Scientific Center for Expertise of Medicinal Products. Regulatory research and examination of medicines. 2013;(1):54—56. (In Russ.)][Krysanov I. S. Simulation modeling by the example of the Monte Carlo simulation method. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2008;(2):3—5. (In Russ.)][Kolbin A. S. Pharmacoeconomical research in oncology based on real clinical practice or modeling. Malignant Tumors. 2012;2(2):26-30. (In Russ.)][Tolkushin A. G., Zyryanov S. K., Pogudina N. L., Davydovskaya M. V. Methods of conducting clinical and economic studies of drugs for the treatment of malignant neoplasms using modeling. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018;11(4):48—60. doi: 10.17749/2070-4909.2018.11.4.048-060. (In Russ.)][Blommestein H. M., Franken M. G., van Beurden-Tan C. H.Y. et al. Cost-effectiveness of novel treatment sequences for transplant-ineligible patients with multiple myeloma. JAMA Netw. Open. 2021;4(3):e213497. doi: 10.1001/jamanetworkopen.2021.3497][Guyot P., Ades A. E., Ouwens M. J., Welton N. J. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan—Meier survival curves. BMC Med. Res. Methodol. 2012;12:9. doi: 10.1186/1471-2288-12-9][Latimer N. R. Survival analysis for economic evaluations alongside clinical trials — extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med. Decis. Making. 2013;33:743—754.][Hoyle M. W., Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med. Res. Methodol. 2011;11:139. doi: 10.1186/1471-2288-11-139][Khaki A. R., Shan Y., Nelson R. E. et al. Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer. Urol. Oncol. 2021;39(10):732.e9—732.e16. doi: 10.1016/j.urolonc.2021.03.004][Magalhães Filho M. A.F., Aguiar P. N.Jr., Neves M. B.M. et al. Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (Sao Paulo). 2022;20:eGS6655. doi: 10.31744/einstein_journal/2022GS6655][Meyers B. M., Vogel A., Marotta P. et al. The cost-effectiveness of lenvatinib in the treatment of advanced or unresectable hepatocellular carcinoma from a Canadian perspective. Canad. J. Gastroenterol. Hepatol. 2021;2021:8811018. doi: 10.1155/2021/8811018][Liu R., Oluwole O. O., Diakite I. et al. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. J. Med. Econom. 2021;24(1):458—468. doi: 10.1080/13696998.2021.1901721][Wang X. J., Wang Y. H., Li S. C.T. et al. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective. J. Med. Econ. 2021;24(1):637—653. doi: 10.1080/13696998.2021.1922066][Sussell J., Singh Jhuti G., Antao V. et al. Cost-effectiveness analysis of ado-trastuzumab emtansine (T-DM1) for the adjuvant treatment of patients with residual invasive HER2+ early breast cancer in the United States. Am. J. Clin. Oncol. 2021;44(7):340—349. doi: 10.1097/COC.0000000000000816][Gil-Rojas Y., Lasalvia P., Hernández F. et al. Cost-effectiveness of the dabrafenib schedule in combination with trametinib compared with other targeted therapies, immunotherapy, and dacarbazine for the treatment of unresectable or metastatic melanoma with BRAFV600 mutation in Colombia. Value Health Reg. Issues. 2021;26:182—190. doi: 10.1016/j.vhri.2021.04.008][Chatterjee A., Shapouri S., Manzoor B. S. et al. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. J. Manag. Care Spec. Pharm. 2021;27(11):1532—1544. doi: 10.18553/jmcp.2021.27.11.1532][Podkonjak T., Cranmer H., Scarisbrick J. et al. Cost-effectiveness of brentuximab vedotin for the treatment of cutaneous T-cell lymphoma. J. Comp. Eff. Res. 2022;11(3):193—202. doi: 10.2217/cer-2021-0201][Braal C. L., Kleijburg A., Jager A. et al. Therapeutic drug monitoring-guided adjuvant tamoxifen dosing in patients with early breast cancer: a cost-effectiveness analysis from the prospective TOTAM trial. Clin. Drug Inv. 2022;42(2):163—175. doi: 10.1007/s40261-021-01114-6][Gao T., Liu J., Wu J. Cost-effectiveness analysis of dabrafenib plus trametinib and vemurafenib as first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in China. Int. J. Environ. Res. Public Health. 2021;18(12):6194. doi: 10.3390/ijerph18126194][Zhu J., Wu Q., Wang J., Niu T. Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia. Exp. Rev. Hematol. 2022;15(4):375—382. doi: 10.1080/17474086.2022.2061456][Annemans L. Health economics for non-economists: an introduction to the concepts, methods and pitfalls of health economic evaluations. Ghent; 2008.][Lemeshko V. A., Musina N. Z., Omelyanovsky V. V. Determination of the therapeutic value of antitumor drugs. Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(3):262—269. (In Russ.)][Tolkushin A. G., Davydovskaya M. V., Yagudina R. I. The concept of determining the equilibrium price of innovative medicines based on their real value — value-based pricing. Remedium. 2017;(12):6—14. (In Russ.)]